Table 2.
Univariate analysis and Cox's proportional hazards models to assess the effect on patient survival of the variables considered in the study
| Univariate | Stepwise variables selection | |||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| Cohort subgroups | ||||||
| SPN/CT+ (N = 376) | 1 | 1 | ||||
| TPN/CT+ (N = 99) | 2.99 | 2.38 to 3.76 | <.001 | 1.35 | 1.03 to 1.77 | .028 |
| SPN/CT‐ (N = 191) | 2.01 | 1.68 to 2.40 | <.001 | 1.46 | 1.20 to 1.77 | <.001 |
| TPN/CT‐ (N = 95) | 4.57 | 3.62 to 5.77 | <.001 | 1.71 | 1.28 to 2.29 | <.001 |
| Sex | ||||||
| Male | 1 | 1 | ||||
| Female | 0.89 | 0.77 to 1.03 | .117 | 0.64 | 0.54 to 0.76 | <.001 |
| Age categories (years) | ||||||
| <70 | 1 | |||||
| ≥70 | 1.77 | 1.50 to 2.08 | <.001 | |||
| Actual weight (kg, continuous) | 0.98 | 0.98 to 0.99 | <.001 | 0.97 | 0.96 to 0.98 | <.001 |
| BMI class | ||||||
| <20.5 kg/m a | 1 | 1 | ||||
| ≥20.5 kg/m2 | 0.71 | 0.61 to 0.82 | <.001 | 1.25 | 1.02 to 1.54 | .033 |
| Weight loss a (%) categories | ||||||
| ≤10.0% | 1 | 1 | ||||
| 10.1%‐15% | 1.56 | 1.28 to 1.90 | <.001 | 1.11 | 0.89 to 1.37 | .355 |
| 15.1%‐20% | 6.91 | 5.53 to 8.65 | <.001 | 2.45 | 1.87 to 3.21 | <.001 |
| >20% | 9.42 | 7.45 to 11.91 | <.001 | 2.94 | 2.22 to 3.90 | <.001 |
| Oral calorie intake (kcal/day) | ||||||
| >1000 | 1 | |||||
| 500‐1000 | 1.86 | 1.24 to 2.80 | .003 | |||
| <500 | 4.97 | 3.28 to 7.52 | <.001 | |||
| Oral protein intake (g/day) | ||||||
| <20 | 1 | 1 | ||||
| ≥20 | 0.37 | 0.32 to 0.43 | <.001 | 0.71 | 0.58 to 0.86 | <.001 |
| Tumor site | ||||||
| Ovary | 1 | |||||
| Gastrointestinal | 0.88 | 0.65 to 1.18 | .392 | |||
| Other | 1.18 | 0.85 to 1.63 | .336 | |||
| Cancer staging | ||||||
| II/III | 1 | 1 | ||||
| IV | 2.80 | 2.36 to 3.33 | <.001 | 1.34 | 1.01 to 1.78 | .044 |
| KPS | ||||||
| 50 | 1 | 1 | ||||
| 60 | 0.58 | 0.46 to 0.74 | <.001 | 0.69 | 0.53 to 0.89 | .005 |
| 70 | 0.23 | 0.18 to 0.29 | <.001 | 0.63 | 0.49 to 0.82 | <.001 |
| 80‐90 | 0.08 | 0.06 to 0.12 | <.001 | 0.33 | 0.22 to 0.50 | <.001 |
| ECOG scale | ||||||
| 1 | 1 | |||||
| 2 | 3.35 | 2.87 to 3.92 | <.001 | |||
| Albumin | ||||||
| <3.5 g/dL | 1 | 1 | ||||
| ≥3.5 g/dL | 0.37 | 0.32 to 0.43 | <.001 | 0.69 | 0.55 to 0.87 | .001 |
| mGPS | ||||||
| 0 | 1 | 1 | ||||
| 1 | 3.63 | 2.87 to 4.57 | <.001 | 3.17 | 2.39 to 4.22 | <.001 |
| 2 | 19.69 | 15.74 to 24.63 | <.001 | 8.35 | 6.35 to 10.97 | <.001 |
All patient characteristics were at the time of home parenteral nutrition start.
Abbreviations: BMI, body mass index; CI, confidence interval; CT‐, no chemotherapy received; CT+, chemotherapy received; ECOG, Eastern Cooperative Oncology Group; KPS, Karnofsky Performance Status; mGPS, modified Glasgow Prognostic Score; SPN, supplemental parenteral nutrition; TPN, total parenteral nutrition.
a
In the last 3 months before home parenteral nutrition (HPN) start.